Brokerages expect that Insmed Incorporated (NASDAQ:INSM) will announce sales of $44.12 million for the current quarter, Zacks reports. Three analysts have issued estimates for Insmed’s earnings, with estimates ranging from $42.50 million to $45.15 million. Insmed posted sales of $9.84 million during the same quarter last year, which would indicate a positive year over year growth rate of 348.4%. The company is scheduled to report its next earnings report on Friday, February 28th.
On average, analysts expect that Insmed will report full year sales of $135.09 million for the current financial year, with estimates ranging from $133.30 million to $135.91 million. For the next fiscal year, analysts expect that the business will report sales of $203.73 million, with estimates ranging from $152.30 million to $221.88 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that follow Insmed.
Insmed (NASDAQ:INSM) last posted its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.01). Insmed had a negative return on equity of 114.68% and a negative net margin of 291.19%. The firm had revenue of $38.89 million during the quarter, compared to the consensus estimate of $35.89 million. During the same quarter last year, the company posted ($1.14) EPS.
NASDAQ INSM traded up $0.03 on Friday, hitting $23.08. The stock had a trading volume of 1,116,149 shares, compared to its average volume of 1,062,296. Insmed has a one year low of $11.31 and a one year high of $33.13. The company has a quick ratio of 6.70, a current ratio of 6.97 and a debt-to-equity ratio of 1.19. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of -5.53 and a beta of 3.04. The company’s 50-day moving average is $19.18 and its two-hundred day moving average is $20.80.
In related news, CAO John Goll sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $20.80, for a total transaction of $520,000.00. Company insiders own 4.95% of the company’s stock.
A number of large investors have recently modified their holdings of INSM. Aperio Group LLC boosted its holdings in Insmed by 21.0% during the second quarter. Aperio Group LLC now owns 11,402 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 1,977 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Insmed by 54.6% during the second quarter. DekaBank Deutsche Girozentrale now owns 51,800 shares of the biopharmaceutical company’s stock worth $1,311,000 after buying an additional 18,300 shares in the last quarter. C WorldWide Group Holding A S boosted its holdings in Insmed by 247.5% during the second quarter. C WorldWide Group Holding A S now owns 393,110 shares of the biopharmaceutical company’s stock worth $10,064,000 after buying an additional 280,000 shares in the last quarter. Swiss National Bank boosted its holdings in Insmed by 9.7% during the second quarter. Swiss National Bank now owns 154,100 shares of the biopharmaceutical company’s stock worth $3,945,000 after buying an additional 13,600 shares in the last quarter. Finally, Hillsdale Investment Management Inc. bought a new stake in Insmed during the second quarter worth approximately $740,000.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Recommended Story: What are the Benefits of Index Funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.